Dimitrios Goumenos

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 589 citations · Full text

Urology, Renal Disease, Renal Events +7

Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

Alberto Ortíz, Mario Cozzolino, Danilo Fliser et al. · Nephrology Dialysis Transplantation · 2020 · 363 citations · Full text

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen et al. · Kidney International · 2022 · 205 citations · Full text

Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy

Krzysztof Kiryluk, Elena Sánchez, Francesca Zanoni et al. · Nature Genetics · 2023 · 156 citations · Full text

Genome-wide Association Study, Glomerulonephritis, Genome-wide Association +15

Keratins are novel markers of renal epithelial cell injury

Sonja Djudjaj, Marios Papasotiriou, Roman D. Bülow et al. · Kidney International · 2016 · 102 citations

Urology, Cell Death, Novel Markers +8